Stribild

Chemical Nameelvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate
Dosage FormTablet (oral; 150mg elvitegravir, 150 mg cobicistat, 200mg emtricitabine, and 300mg tenofovir disoproxil fumarate)
Drug ClassAntivirals
SystemBlood
CompanyGilead Sciences
Approval Year2012

Indication

  • Indicated as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older weighing at least 35 kg who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies/mL) on a stable antiretroviral regimen for at least 6 months with no history of treatment failure and no known substitutions associated with resistance to the individual components of STRIBILD
Last updated on 4/21/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?